# SSX1

## Overview
The SSX1 gene is a member of the synovial sarcoma X (SSX) gene family, which is known for its role in encoding proteins that function as transcriptional corepressors. The protein encoded by SSX1, known as SSX family member 1, is characterized by its involvement in chromatin remodeling and gene expression regulation. It is primarily expressed in the testis and thyroid, and it plays a significant role in cellular processes through interactions with polycomb group proteins and other chromatin regulators. SSX1 is particularly notable for its involvement in synovial sarcoma, where it forms fusion proteins with the SS18 gene, contributing to oncogenic processes. The SSX1 protein lacks a DNA-binding domain but contains functional domains such as the Krüppel-associated box (KRAB) domain and the SSX repression domain (SSXRD), which are crucial for its transcriptional repression activities (de2002The; Zöllner2015Synovial).

## Structure
The SSX1 protein is a member of the SSX gene family, characterized by a high degree of homology among its members, with 77 to 91% identity at the protein level (de2002The). The SSX1 protein is composed of 188 amino acids and is rich in charged amino acids. It contains consensus sequences for N-glycosylation and tyrosine phosphorylation, indicating potential sites for post-translational modifications (de2002The). The protein features a conserved acidic C-terminal tail and an N-terminal region that shows homology to the KRAB domain, a known transcriptional repressor domain (de2002The; Güre2002The).

The SSX1 protein lacks a DNA-binding domain but can repress transcription in transfected cells, a function attributed to its conserved C-terminal domain, known as the SSXRD domain. This domain is crucial for nuclear localization and colocalization with mitotic chromosomes and polycomb-group nuclear bodies (de2002The). The SSXRD domain is also present in SYT-SSX fusion proteins, highlighting its importance in the function of both SSX and SYT-SSX fusion proteins (de2002The). The SSX proteins, including SSX1, are typically expressed in the testis and thyroid and are involved in synovial sarcoma through fusion with the SYT gene due to the t(X;18) translocation (de2002The).

## Function
The SSX1 gene encodes a protein that functions primarily as a transcriptional corepressor, playing a significant role in chromatin remodeling and gene expression regulation. SSX1 proteins are characterized by their localization in the nucleus, where they interact with polycomb group (PcG) proteins, which are involved in maintaining the repressed state of target genes through epigenetic chromatin modifications (Zöllner2015Synovial; de2006The). The SSX1 protein contains several functional domains, including the Krüppel-associated box (KRAB) domain and the SSX repression domain (SSXRD), which are crucial for its transcriptional repression activities (Zöllner2015Synovial).

In healthy human cells, SSX1 is primarily expressed in the testis and, to a lesser extent, in the thyroid (de2002The). The protein's interaction with DNA-binding proteins, such as the LIM homeobox protein LHX4, suggests a role in cellular proliferation and antiapoptotic activities (de2006The). Although SSX1's specific function in normal cells is not fully detailed, its involvement in transcriptional repression and chromatin remodeling indicates its importance in regulating gene expression and maintaining cellular homeostasis (Zöllner2015Synovial; de2006The).

## Clinical Significance
The SSX1 gene is clinically significant due to its involvement in synovial sarcoma, a type of soft tissue cancer. This gene frequently forms fusion proteins with the SS18 gene, resulting in the SS18-SSX1 oncoprotein, which is a hallmark of synovial sarcoma. This fusion protein lacks a DNA binding domain and exerts its oncogenic effects by interacting with chromatin regulators, particularly through hijacking the KDM2B-PRC1.1 repressive complex to activate gene expression aberrantly (Banito2018The). The SS18-SSX1 fusion protein also interacts with components of the SWI/SNF complex and polycomb group proteins, affecting the balance between transcriptional activation and repression (Banito2018The).

Alterations in SSX1 expression or interactions can lead to aberrant gene activation, contributing to the development of synovial sarcoma (Benabdallah2023Aberrant). The SSX1 gene can also form novel fusions with other genes, such as EWSR1 and MN1, which share similar transcriptional signatures and mechanisms of action in synovial sarcoma (Yoshida2022Identification). These findings highlight the gene's role in the pathogenesis of synovial sarcoma and suggest that SSX1 fusions are associated with a broader range of genetic alterations than previously understood (Yoshida2022Identification).

## Interactions
The SSX1 protein, a member of the SSX gene family, is involved in several protein interactions that influence transcriptional regulation. SSX1 is known to interact with components of the Polycomb group (PcG) complexes, which are involved in chromatin remodeling and transcriptional repression (de2002The). These interactions are facilitated by the conserved C-terminal domain of SSX proteins, known as the SSXRD, which is responsible for nuclear localization and interaction with polycomb-group nuclear bodies (de2002The).

In the context of synovial sarcoma, SSX1 is part of the SYT-SSX1 fusion protein resulting from a chromosomal translocation. This fusion protein interacts with the chromatin remodeling factor hBRM/hSNF2α, which plays a role in transcriptional regulation and cellular transformation (Nagai2001Analysis). The interaction between SYT-SSX1 and hBRM/hSNF2α is crucial for the transforming activity of the fusion protein, potentially through the regulation of tumor suppressor genes such as DCC (Nagai2001Analysis).

These interactions highlight the role of SSX1 in modulating chromatin structure and gene expression, contributing to its involvement in oncogenic processes.


## References


[1. (Nagai2001Analysis) Makoto Nagai, Shinya Tanaka, Masumi Tsuda, Shuichi Endo, Hiroyuki Kato, Hiroshi Sonobe, Akio Minami, Hiroaki Hiraga, Hiroshi Nishihara, Hirofumi Sawa, and Kazuo Nagashima. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein syt-ssx1 bound to chromatin remodeling factor hbrm/hsnf2α. Proceedings of the National Academy of Sciences, 98(7):3843–3848, March 2001. URL: http://dx.doi.org/10.1073/pnas.061036798, doi:10.1073/pnas.061036798. This article has 146 citations.](https://doi.org/10.1073/pnas.061036798)

[2. (de2002The) Diederik R.H. de Bruijn, Nuno R. dos Santos, Ellen Kater‐Baats, José Thijssen, Lieke van den Berk, Jiska Stap, Matthé Balemans, Marga Schepens, Gerard Merkx, and Ad Geurts van Kessel. The cancer‐related protein ssx2 interacts with the human homologue of a ras‐like gtpase interactor, rab3ip, and a novel nuclear protein, ssx2ip. Genes, Chromosomes and Cancer, 34(3):285–298, March 2002. URL: http://dx.doi.org/10.1002/gcc.10073, doi:10.1002/gcc.10073. This article has 47 citations.](https://doi.org/10.1002/gcc.10073)

[3. (Güre2002The) Ali O. Güre, Isaac J. Wei, Lloyd J. Old, and Yao‐Tseng Chen. The ssx gene family: characterization of 9 complete genes. International Journal of Cancer, 101(5):448–453, September 2002. URL: http://dx.doi.org/10.1002/ijc.10634, doi:10.1002/ijc.10634. This article has 99 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.10634)

[4. (Zöllner2015Synovial) Stefan K. Zöllner, Claudia Rössig, and Jeffrey A. Toretsky. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer. Cancer and Metastasis Reviews, 34(3):417–428, August 2015. URL: http://dx.doi.org/10.1007/s10555-015-9575-z, doi:10.1007/s10555-015-9575-z. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10555-015-9575-z)

[5. (Benabdallah2023Aberrant) Nezha S. Benabdallah, Vineet Dalal, R. Wilder Scott, Fady Marcous, Afroditi Sotiriou, Felix K. F. Kommoss, Anastasija Pejkovska, Ludmila Gaspar, Lena Wagner, Francisco J. Sánchez-Rivera, Monica Ta, Shelby Thornton, Torsten O. Nielsen, T. Michael Underhill, and Ana Banito. Aberrant gene activation in synovial sarcoma relies on ssx specificity and increased prc1.1 stability. Nature Structural &amp; Molecular Biology, 30(11):1640–1652, September 2023. URL: http://dx.doi.org/10.1038/s41594-023-01096-3, doi:10.1038/s41594-023-01096-3. This article has 5 citations.](https://doi.org/10.1038/s41594-023-01096-3)

[6. (de2006The) Diederik R. H. de Bruijn, Jan‐Peter Nap, and Ad Geurts van Kessel. The (epi)genetics of human synovial sarcoma. Genes, Chromosomes and Cancer, 46(2):107–117, November 2006. URL: http://dx.doi.org/10.1002/gcc.20399, doi:10.1002/gcc.20399. This article has 44 citations.](https://doi.org/10.1002/gcc.20399)

[7. (Yoshida2022Identification) Akihiko Yoshida, Yasuhito Arai, Kaishi Satomi, Takashi Kubo, Eijitsu Ryo, Yuko Matsushita, Natsuko Hama, Kazuki Sudo, Motokiyo Komiyama, Yasushi Yatabe, Tatsuhiro Shibata, Hitoshi Ichikawa, Koichi Ichimura, Akira Kawai, and Taisuke Mori. Identification of novel ssx1 fusions in synovial sarcoma. Modern Pathology, 35(2):228–239, February 2022. URL: http://dx.doi.org/10.1038/s41379-021-00910-x, doi:10.1038/s41379-021-00910-x. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41379-021-00910-x)

[8. (Banito2018The) Ana Banito, Xiang Li, Aimée N. Laporte, Jae-Seok Roe, Francisco Sanchez-Vega, Chun-Hao Huang, Amanda R. Dancsok, Katerina Hatzi, Chi-Chao Chen, Darjus F. Tschaharganeh, Rohit Chandwani, Nilgun Tasdemir, Kevin B. Jones, Mario R. Capecchi, Christopher R. Vakoc, Nikolaus Schultz, Marc Ladanyi, Torsten O. Nielsen, and Scott W. Lowe. The ss18-ssx oncoprotein hijacks kdm2b-prc1.1 to drive synovial sarcoma. Cancer Cell, 33(3):527-541.e8, March 2018. URL: http://dx.doi.org/10.1016/j.ccell.2018.01.018, doi:10.1016/j.ccell.2018.01.018. This article has 94 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.ccell.2018.01.018)